Losartan to Reverse Sickle Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
NephropathySickle Cell Anemia
Interventions
DRUG

Losartan

Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months

Trial Locations (9)

20892

NHLBI, Bethesda

40201

University of Louisville, Louisville

43205

Nationwide Children's Hospital, Columbus

44308

Akron Children's Hospital, Akron

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

University of Cincinnati, Cincinnati

60612

University of Illinois at Chicago, Chicago

75390

University of Texas Southwestern, Dallas

77030

Texas Children's Hospital, Houston

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT01479439 - Losartan to Reverse Sickle Nephropathy | Biotech Hunter | Biotech Hunter